Apex Medical / Insights
What's moving across MedTech — and what matters commercially.
Two things live here. Current industry developments, aggregated from public sources so the page stays current. And Apex's own writing, which is deliberately infrequent and only on subjects we can speak to from having done the work.
Apex Insights
Original writingCommercial perspectives on MedTech growth
Practical analysis on market entry, commercialization, channel strategy, procurement, diligence and the decisions that determine whether a medical technology actually gains traction. Apex writes on a small number of subjects it can speak to from experience rather than publishing to a content calendar — the programme below is what's underway.
The commercial guide to entering the Canadian medical device market
Procurement, provincial funding, channel economics and launch sequencing — the part regulatory guidance does not cover, written for the commercial team rather than the regulatory one.
In development · cornerstoneWhy cleared devices fail to sell
The recurring commercial failure modes after clearance, and which of them are still recoverable once a launch has stalled.
In developmentThe revenue plan nobody stress-tested
How to check whether a MedTech forecast is physically deliverable by the commercial organisation expected to deliver it.
In developmentHow Canadian hospitals actually buy
Value-analysis committees, group purchasing and provincial tender cycles, and what each one does to a price.
PlannedWhere AI actually helps a commercial team — and where it doesn't
A restrained view from someone using it inside real engagements rather than selling it.
PlannedSomething in the feed relevant to your market?
If a development changes your commercial position and you want a second read on it, that is a reasonable reason to get in touch.